Adma Biologics reported $56.49M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Adma Biologics USD 56.49M 18.45M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Dynavax Technologies USD 106.84M 11.39M Sep/2025
Takeda JPY 2.61T 470.53B Dec/2025